Checchi Capital Advisers LLC Sells 471 Shares of Becton, Dickinson and Company $BDX

Checchi Capital Advisers LLC trimmed its position in Becton, Dickinson and Company (NYSE:BDX) by 20.2% in the second quarter, HoldingsChannel.com reports. The firm owned 1,863 shares of the medical instruments supplier’s stock after selling 471 shares during the period. Checchi Capital Advisers LLC’s holdings in Becton, Dickinson and Company were worth $321,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC lifted its holdings in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the period. NBC Securities Inc. bought a new position in Becton, Dickinson and Company during the first quarter worth about $102,000. Congress Asset Management Co. lifted its stake in Becton, Dickinson and Company by 7.9% during the first quarter. Congress Asset Management Co. now owns 1,892 shares of the medical instruments supplier’s stock worth $433,000 after purchasing an additional 139 shares during the period. Miracle Mile Advisors LLC boosted its holdings in Becton, Dickinson and Company by 11.8% during the first quarter. Miracle Mile Advisors LLC now owns 1,520 shares of the medical instruments supplier’s stock valued at $348,000 after purchasing an additional 160 shares in the last quarter. Finally, Capital Investment Advisors LLC grew its stake in shares of Becton, Dickinson and Company by 4.8% in the 1st quarter. Capital Investment Advisors LLC now owns 2,030 shares of the medical instruments supplier’s stock valued at $465,000 after purchasing an additional 93 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.9%

Shares of NYSE BDX opened at $191.94 on Tuesday. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The firm’s 50-day simple moving average is $189.21 and its 200 day simple moving average is $186.79. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The company has a market cap of $55.02 billion, a price-to-earnings ratio of 34.52, a price-to-earnings-growth ratio of 1.51 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping analysts’ consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. During the same period in the previous year, the firm posted $3.50 earnings per share. The company’s revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date was Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 74.82%.

Analysts Set New Price Targets

Several analysts recently commented on BDX shares. Wells Fargo & Company boosted their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research note on Friday, August 8th. Royal Bank Of Canada initiated coverage on shares of Becton, Dickinson and Company in a research note on Thursday, September 25th. They issued a “sector perform” rating and a $211.00 target price on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Saturday, September 27th. Piper Sandler reissued a “neutral” rating and set a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Finally, Argus upped their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Hold” and an average price target of $205.40.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Claire Fraser sold 917 shares of the company’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,023 shares of company stock valued at $562,036 over the last three months. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.